spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

BioIVT

Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development


Westbury, NY – August 8, 2022
– BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.

“We are delighted that the Cypex team is joining BioIVT, bringing with them not only their market-leading products, but also their in vitro drug metabolism technology expertise,” said BioIVT Chief Executive Officer Richard Haigh. “The acquisition of Cypex enhances BioIVT’s product portfolio, ensuring that we continue to meet all our biopharmaceutical customers’ research requirements for their entire R&D pipeline.”

“This is a good match. We view BioIVT as a like-minded partner; we share the same commitment to supplying high quality products and passion for ensuring that our customers have the best products for their research,” said Dr. Michael Voice, Co-lead Scientist at Cypex. “We are excited that our customers will gain access to BioIVT’s hepatocytes and other hepatic products, and benefit from its well-established global biospecimen network, and robust supply chain.”

Product Development

Cypex’s products are produced using a patented technology, which was developed by the University of Dundee in partnership with several leading international pharmaceutical companies. This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.

Since the introduction of its first recombinant CYP enzyme in early 2000, Cypex has built an extensive product range, which contains more than 115 recombinant enzymes, including CYPs, UGTs, CES, and AOX, and companion chemicals and media. Also offered are services for inhibition screening, protein expression and drug metabolite generation. These products and services are used to generate in vitro data showing how a candidate drug will be metabolized in the human body, data often included in new drug applications to regulatory agencies.

BioIVT will continue to operate from the ISO 9001 certified manufacturing facility in Dundee. Financial details about this transaction were not disclosed.
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 
Print this page
Send to a friend
   
spacer
News and Press Releases

GSK Completes Acquisition of Sierra Oncology

London, UK, 1 July, 2022: GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.
More info >>


White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement